Is Sermorelin / GHRP legal in the United Kingdom?

The standard compounding pharmacy growth hormone blend, usually sold as 5 mg sermorelin with 5 mg GHRP-2 in one 10 mg vial. This is the only blend on this site where the class combination has genuine human data: adding a GHRH to GHRP-6 roughly doubled the acute growth hormone peak, 54.7 against 25.7 micrograms per litre in 20 patients. That was a single intravenous diagnostic test in a hospital, not a nightly subcutaneous protocol, and the specific vial has never been studied.

Sermorelin plus a growth hormone releasing peptide is the oldest configuration of this idea and the one with the most real science underneath it. Sermorelin is GHRH 1-29, the shortest fully active fragment of growth hormone releasing hormone, and it was an FDA-approved drug marketed as Geref for diagnosing and treating growth hormone deficiency before it was discontinued.

Mechanism: Sermorelin activates the pituitary GHRH receptor, raising growth hormone pulse amplitude while preserving hypothalamic feedback. GHRP-2 and GHRP-6 activate the growth hormone secretagogue receptor GHS-R1a, a separate receptor cloned in 1996, releasing growth hormone and suppressing somatostatin tone.

Regulatory history: Not approved as a blend. Sermorelin was previously FDA-approved as Geref and is now supplied compounded; GHRP-2 is approved in Japan as a diagnostic agent only; GHRP-6 is not approved anywhere.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Sermorelin / GHRP at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.